SCHEMBL2886689

SCHEMBL2886689

CN(C)C1CCN(Cc2ccc(Cn3cnc4ccccc43)c(Cl)c2)C1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.57
CYP11B1 P15538 7/20 0.45
CYP11B2 P19099 7/20 0.45
HTT P42858 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPK1 P28482 1/20 0.45
LMNA P02545 2/20 0.44
TNF P01375 2/20 0.43
LTA4H P09960 1/20 0.43
DDR1 Q08345 2/20 0.42
ALDH1A1 P00352 1/20 0.42
CHRM1 P11229 1/20 0.41
HRH1 P35367 1/20 0.41
KCNH2 Q12809 1/20 0.41
NSD2 O96028 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2884425 0.93 HRH3 (0.49) HRH3CYP11B1CYP11B2HTTSMN1; SMN2
SCHEMBL2881480 0.86 HRH3 (0.60) HRH3CYP11B1CYP11B2HTTSMN1; SMN2
SCHEMBL2883537 0.83 HRH3 (0.57) HRH3CYP11B1CYP11B2HTTSMN1; SMN2
SCHEMBL2884414 0.82 HRH3 (0.56) HRH3CYP11B1CYP11B2HTTSMN1; SMN2
SCHEMBL2891615 0.81 BACE1 (0.42) HRH3CYP11B1CYP11B2HTTSMN1; SMN2
SCHEMBL2881324 0.78 HRH3 (0.52) HRH3CYP11B1CYP11B2HTTSMN1; SMN2
SCHEMBL2883883 0.77 HRH3 (0.52) HRH3LTA4HDDR1HRH1KCNH2
SCHEMBL2886675 0.77 HRH3 (0.52) HRH3LTA4HDDR1ALDH1A1HRH1
SCHEMBL1813650 0.76 HRH3 (0.46) HRH3CYP11B1CYP11B2HTTLTA4H
SCHEMBL2891618 0.73 CYP11B1 (0.45) HRH3CYP11B1CYP11B2HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820825-B2 N-substituted-azacyclylamines as histamine-3 antagonists WYETH LLC (US) 2010-10-26 US claimed
US-20070219240-A1 N-substituted-azacyclylamines as histamine-3 antagonists WYETH (US) 2007-09-20 US claimed
US-7820825-B2 N-substituted-azacyclylamines as histamine-3 antagonists WYETH LLC (US) 2010-10-26 US disclosed
EP-1994022-A2 N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS Wyeth a Corporation of the State of Delaware (US) 2008-11-26 EP disclosed
WO-2007108936-A2 N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2007-09-27 WO disclosed
US-20070219240-A1 N-substituted-azacyclylamines as histamine-3 antagonists WYETH (US) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219240-A1 N-substituted-azacyclylamines as histamine-3 antagonists HNMT, HRH4, HRH3 HRH3 3/4885CYP11B1 2856/4885CYP11B2 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.